A Phase I, Single Centre, Open, Partly Randomised, Crossover Study in Healthy Subjects to Evaluate AZD5423 Absolute Pulmonary Bioavailability When Administered Inhaled Via a New Dry Powder Inhaler, Turbuhaler, Spira Nebulizer and I-neb AAD System
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2013
At a glance
- Drugs AZD 5423 (Primary) ; AZD 5423 (Primary) ; AZD 5423 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Aug 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 09 Aug 2012 Actual initiation date (Aug 2012) added as reported by ClinicalTrials.gov.